Pharmazz Strengthens Its Patent Portfolio With Notice Of Issuance For PMZ-2123 (BQ123) In The Treatment Of Diabetic Ketoacidosis
NAPERVILLE, Ill., April 22, 2016 /PRNewswire/ -- Pharmazz, Inc. is a clinical-stage company developing innovative therapeutics in the area of critical care medicine. The company announced that a Notice of Issuance was received from the China Patent Office, for the patent application regarding composition and methods of use for treating diabetic ketoacidosis (DKA). Pharmazz has exclusive global rights of this technology from Midwestern University with following issued patents: Japanese Patent Application No. 2012-508762; United States Patent No. 8,980,874; European Patent No. EP2424530; Australian Patent No. 61/174,283; China patent application No. 201080030271.1. The patent issued includes the Company's lead clinical candidate, PMZ-2123, which is currently being developed as an injectable preparation for the treatment of DKA. Pharmazz had a pre-IND meeting with US FDA for phase II clinical studies on PMZ-2123.
"We are pleased to have been granted this Notice of Issuance from the China Patent Office," said Dr. Anil Gulati, Inventor and founder of Pharmazz. He added that, "This patent protection further strengthens the company's position to generate business and commercial development opportunities and is a step closer towards better treatment for DKA patients."
About Diabetic Ketoacidosis (DKA)
DKA is the most serious acute complication of type 1 diabetes resulting in hospitalization with a mortality rate of 0.15 to 0.3% and escalates the diabetes related costs up to 3.6 folds compared to diabetic patients without DKA. Patients with type 2 diabetes getting DKA are also on the rise. In a rat model of DKA PMZ-2123 (BQ-123; selective ETA receptor antagonist) rapidly normalizes the blood ketone levels, improves arterial blood pH and prevents insulin induced increase in cerebral perfusion. High levels of ketone can be dangerously harmful to the body; PMZ-2123 when used with insulin can rapidly lower the blood ketone levels. PMZ-2123 has been extensively used in clinical studies without any serious adverse effects.
About Pharmazz, Inc.
Pharmazz, Inc. is a privately-held company engaged in the development of novel products in the area of critical care medicine. Pharmazz is developing PMZ-2010 (centhaquin) as a resuscitative agent having a unique property of increasing blood pressure and cardiac output, and decreasing vascular resistance in hypovolemic shock. The company successfully completed human Phase I study of PMZ-2010 (NCT02408731; CTRI/2014/06/004647). A pre-IND meeting for phase II clinical studies was held with US FDA and Pharmazz is completing the required regulatory studies. Patents titled "Novel therapeutic treatments using centhaquin" have been issued: Australia Patent No. 2010241564; Japan Patent No. 5498571 and 5727642; China Patent No. 201080029672.5. In addition, the company is developing PMZ-1620 which is a neuroregenerative agent that produces neurogenesis and angiogenesis in the damaged area of the brain by stimulating endogenous regenerative mechanisms. US patent titled "Methods for treatment of stroke or cerebrovascular accidents using IRL-1620" US Patent No. 8,623,823 has been issued. China patent titled "Compositions for the treatment of stroke or cerebrovascular accidents with an endothelin B receptor agonist" China patent No. ZL 2008 8 0113425.6 and European Patent Number EP2182977 have been issued. Potential indications of this product can be for the treatment of stroke, Alzheimer's disease, ALS, spinal cord injuries etc.
We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities. Additional information may be found on the Company's website, www.pharmazz.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are projections of events, revenues, income, future economic, research, development, reformulation, product performance or management's plans and objectives for future operations. In some cases you can identify forward-looking statements by the use of terminology such as "may", "should", "anticipates", "believes", "expects", "intends", "forecasts", "plans", "future", "strategy", or words of similar meaning. Forward-looking statements in this presentation include statements about the product(s) Pharmazz, Inc. owns, may own, license, co-promote, co-develop, co-market or otherwise enter into an arrangement with other parties. While these forward-looking statements and any assumptions upon which they are based are made in good faith and reflect current judgment regarding the direction of the business operations of Pharmazz, Inc. actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this presentation. These statements are predictions and involve known and unknown risks, uncertainties and other factors, including the risk that Pharmazz, Inc. cannot execute its business plan for lack of capital or other resources, distribution, partnering or licensing/acquisition opportunities. Any of these risks could cause Pharmazz, Inc. or its industry's, actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements in this presentation. Except as required by applicable law Pharmazz, Inc. does not intend to update any of the forward-looking statements to conform these statements to actual results.
Contact
Pharmazz, Inc.
Shruti Gulati
630-780-6087
shruti.gulati@pharmazz.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pharmazz-inc-strengthens-its-patent-portfolio-with-notice-of-issuance-for-pmz-2123-bq123-in-the-treatment-of-diabetic-ketoacidosis-300255717.html
SOURCE Pharmazz, Inc.
